<DOC>
	<DOCNO>NCT00956332</DOCNO>
	<brief_summary>The purpose study evaluate safety activity two dos MultiGeneAngio , cell therapy product produce patient 's cell , potential treatment patient chronic critical limb ischemia .</brief_summary>
	<brief_title>Safety Study MultiGeneAngio Patients With Chronic Critical Limb Ischemia</brief_title>
	<detailed_description>Approximately 16 million patient worldwide ( 1 20 people age 50 ) suffer peripheral arterial disease ( PAD ) . PAD characterize narrow occlusion vessel supply blood low limb , often due atherosclerosis . Symptoms PAD include claudication may progress critical limb ischemia manifest rest pain , tissue loss gangrene , eventually may necessitate amputation . MultiGeneAngio cell therapy-based product develop treatment patient chronic critical limb ischemia due narrow block leg artery . MultiGeneAngio compose endothelial smooth muscle cell isolate short vein segment harvest patient 's arm . After isolation cell expand , characterize , gene modify transfer angiogenic gene . MultiGeneAngio clear cell suspension inject intra-arterially site blockage use standard diagnostic catheter , order create expand new collateral artery , thereby improve blood flow ischemic limb . Comprehensive pre-clinical study , well clinical experience PAD patient suffer claudication show production administration MultiGeneAngio feasible safe , apparent drug-related adverse event observe . Moreover , follow-up data peak walk time imply beneficial trend efficacy end-point . Additional follow-up data continue collect help evaluate safety efficacy MultiGeneAngio .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Men woman 50 year age old Ischemic rest pain ( Rutherford category 4 ) and/or Nonhealing wound ( Rutherford category 5 ) ABI 0.5 less , TBI 0.3 less Ankle systolic pressure 70 mm Hg le , toe systolic pressure 50 mm Hg le Poor option conventional revascularization Life expectancy less one year Presence significant inflow disease ( &gt; 50 % stenosis ) distal aorta , common external iliac Advanced CLI , characterize extensive tissue loss gangrene ( Rutherford category 6 ) Previous major amputation leg treat planned major amputation within month enrollment Evidence osteomyelitis Ischemic wound uncontrolled infectious symptom Heart angioplasty CABG within 3 month prior enrollment Severe congestive heart failure ( New York Heart Association stage IV ) Acute cardiovascular event within 3 month prior enrollment Uncontrolled blood pressure : SBP≥ 180 mmHg DBP ≥110 mmHg Known Buerger 's disease History bleeding diathesis ( e.g. , hemophilia due Factor VIII IX deficiency ) Renal failure define serum creatinine &gt; 2.5mg/dL Significant hepatic disease : &gt; 3fold elevation ALT/AST , HBV HCV carrier Severe pulmonary disease Active proliferative retinopathy and/or severe macular oedema Intraocular surgery within 6 month prior enrollment Immunodeficient state ( e.g . know HIV positivity , organ transplant recipient ) subject receive immunosuppressive medication History malignant neoplasm ( except curable nonmelanoma skin malignancy ) within 5 year prior enrollment Pregnant lactate woman Previous treatment angiogenic growth factor stem cell No demonstrable venous access Known hypersensitivity VEGF , Angiopoietin1 , heparin</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Peripheral arterial disease ( PAD )</keyword>
	<keyword>Peripheral vascular disease ( PVD )</keyword>
	<keyword>Critical limb ischemia ( CLI )</keyword>
	<keyword>Cell therapy</keyword>
	<keyword>Gene therapy</keyword>
	<keyword>Endothelial cell</keyword>
	<keyword>Smooth muscle cell</keyword>
	<keyword>Angiogenesis</keyword>
	<keyword>Arteriogenesis</keyword>
	<keyword>amputation</keyword>
	<keyword>diabetic foot</keyword>
</DOC>